Datroway Achieves First OS Benefit in Immunotherapy-Ineligible Triple-Negative Breast Cancer
First cancer drug to show OS benefit vs chemotherapy for TNBC patients ineligible for immunotherapy in landmark phase 3 trial.
Triple Negative Breast Cancer (TNBC)
Latest Posts
ASCENT-03: Trodelvy Plus Pembrolizumab Demonstrates Significant PFS Benefit in First-Line Metastatic Triple-Negative Breast Cancer
ASCENT-03 trial shows Trodelvy plus pembrolizumab significantly improved PFS vs chemo plus pembrolizumab in first-line...
ENPP1 Inhibition Plus Radiation Prevents Breast Cancer Local Recurrence in Preclinical Models
ENPP1hi circulating tumor cells contribute to relapse by self-seeding mechanism requiring PMN-MDSC infiltration and NET...
